Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Earnings Release Classification · 95% confidence The document is a current report on SEC Form 8-K with Item 2.02 “Results of Operations and Financial Condition,” furnishing a press release announcing first quarter 2026 financial results. It is an initial earnings announcement for a quarterly period rather than a full interim report containing detailed financial statements. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-14 English
ARS - AEON Biopharma, Inc. (0001837607) (Filer)
Annual Report
2026-04-29 English
DEF 14A - AEON Biopharma, Inc. (0001837607) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
4 - AEON BIOPHARMA, INC. (0001837607) (Filer)
Director's Dealing
2026-02-20 English
424B3 Filing
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares of common stock by registered holders. It includes detailed information about the securities being offered, registration rights, and the plan of distribution. The document is a formal offering document used in capital markets to inform investors about a securities offering. This type of document is related to capital raising and financing activities rather than financial reporting, management changes, or other categories. Therefore, it fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual prospectus itself.
2026-02-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.